Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126026504 | 12602650 | 4 | F | 2016 | 20160825 | 20160728 | 20160901 | EXP | JP-GLAXOSMITHKLINE-JP2016JPN107026 | GLAXOSMITHKLINE | 17.88 | YR | F | Y | 52.00000 | KG | 20160901 | PH | JP | JP |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126026504 | 12602650 | 1 | PS | LAMICTAL | LAMOTRIGINE | 1 | Oral | UNK UNK, 1D | 525 | MG | Y | 20241 | TABLET | ||||||
126026504 | 12602650 | 2 | SS | LAMICTAL | LAMOTRIGINE | 1 | Oral | 25 MG, 1D | 525 | MG | Y | 20241 | 25 | MG | TABLET | QD | |||
126026504 | 12602650 | 3 | SS | LAMICTAL | LAMOTRIGINE | 1 | Oral | 50 MG, 1D | 525 | MG | Y | 20241 | 50 | MG | TABLET | QD | |||
126026504 | 12602650 | 4 | SS | LAMICTAL | LAMOTRIGINE | 1 | Oral | 25 MG, 1D | 525 | MG | Y | 20241 | 25 | MG | TABLET | QD | |||
126026504 | 12602650 | 5 | SS | DEPAKENE | VALPROIC ACID | 1 | Oral | 400 MG, BID | 7200 | MG | Y | 0 | 400 | MG | BID | ||||
126026504 | 12602650 | 6 | C | ABILIFY | ARIPIPRAZOLE | 1 | 3 MG, 1D | 135 | MG | 0 | 3 | MG | QD | ||||||
126026504 | 12602650 | 7 | C | ABILIFY | ARIPIPRAZOLE | 1 | 6 MG, 1D | 135 | MG | 0 | 6 | MG | QD | ||||||
126026504 | 12602650 | 8 | C | ABILIFY | ARIPIPRAZOLE | 1 | 12 MG, 1D | 135 | MG | 0 | 12 | MG | QD | ||||||
126026504 | 12602650 | 9 | C | ABILIFY | ARIPIPRAZOLE | 1 | 6 MG, 1D | 135 | MG | 0 | 6 | MG | QD | ||||||
126026504 | 12602650 | 10 | C | SEROQUEL | QUETIAPINE FUMARATE | 1 | 100 MG, 1D | 200 | MG | 0 | 100 | MG | QD | ||||||
126026504 | 12602650 | 11 | C | FERROUS SULFATE. | FERROUS SULFATE | 1 | 210 MG, 1D | 2730 | MG | 0 | 210 | MG | QD | ||||||
126026504 | 12602650 | 12 | C | BELSOMRA | SUVOREXANT | 1 | 15 MG, 1D | 135 | MG | 0 | 15 | MG | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126026504 | 12602650 | 1 | Bipolar disorder |
126026504 | 12602650 | 5 | Bipolar disorder |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126026504 | 12602650 | HO |
126026504 | 12602650 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126026504 | 12602650 | Blister | |
126026504 | 12602650 | Conjunctival hyperaemia | |
126026504 | 12602650 | Glossodynia | |
126026504 | 12602650 | Headache | |
126026504 | 12602650 | Lip erosion | |
126026504 | 12602650 | Lip swelling | |
126026504 | 12602650 | Ocular hyperaemia | |
126026504 | 12602650 | Oral herpes | |
126026504 | 12602650 | Pyrexia | |
126026504 | 12602650 | Rash | |
126026504 | 12602650 | Rash papular | |
126026504 | 12602650 | Rash pruritic | |
126026504 | 12602650 | Somnolence | |
126026504 | 12602650 | Stevens-Johnson syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126026504 | 12602650 | 2 | 20160428 | 20160502 | 0 | |
126026504 | 12602650 | 3 | 20160502 | 20160506 | 0 | |
126026504 | 12602650 | 4 | 20160506 | 20160516 | 0 | |
126026504 | 12602650 | 5 | 20160506 | 20160520 | 0 | |
126026504 | 12602650 | 6 | 20160427 | 20160502 | 0 | |
126026504 | 12602650 | 7 | 20160502 | 20160506 | 0 | |
126026504 | 12602650 | 8 | 20160506 | 20160513 | 0 | |
126026504 | 12602650 | 9 | 20160513 | 20160516 | 0 | |
126026504 | 12602650 | 10 | 20160513 | 20160516 | 0 | |
126026504 | 12602650 | 11 | 20160502 | 20160516 | 0 | |
126026504 | 12602650 | 12 | 20160506 | 20160516 | 0 |